Summit Therapeutics Q3 Adj. EPS $(0.20) Beats $(0.28) Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 53.85 percent decrease over losses of $(0.13) per share
Summit Therapeutics (NASDAQ:SMMT) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 53.85 percent decrease over losses of $(0.13) per share from the same period last year.